Jerome Powell: Fed credibility at risk if presidents can fire officials

Kyntra Bio targets FG-3246 median rPFS of 10 months or greater as it plans roxadustat Phase III start in Q4 2026

ARS Pharma targets cash flow breakeven by end of 2027 as it cuts cash-based SG&A and R&D to $100M-$110M in H2 2026

Soluna outlines 70%-80% project debt plan for 100-MW AI builds, while expecting 206 MW operating by end of summer

Goldman Sachs lines up investors for Nvidia’s $500B AI funding plan - report